Management of Spironolactone and Chlorthalidone in HFpEF

Rationale for Continuing Spironolactone

The European Society of Cardiology recommends that in symptomatic HFpEF patients with blood pressure above target, MRAs like spironolactone may be considered to reduce heart failure hospitalizations and reduce blood pressure, as supported by the 2024 ESC guidelines 1, 2
Spironolactone functions as a mineralocorticoid receptor antagonist with proven benefits for reducing heart failure hospitalizations and cardiovascular mortality in HFpEF patients, particularly those with lower ejection fractions within the preserved range, according to the European Heart Journal 1, 3
Post-hoc analysis from TOPCAT demonstrated that spironolactone reduced the composite endpoint of cardiovascular death, heart failure hospitalization, or resuscitated sudden death in HFpEF patients, driven mainly by cardiovascular mortality reduction, as reported in Circulation 3, 4

Spironolactone and chlorthalidone work through entirely different mechanisms: spironolactone blocks aldosterone receptors providing neurohormonal antagonism, while chlorthalidone acts as a thiazide-like diuretic blocking sodium-chloride cotransport in the distal tubule, as described in the European Heart Journal and European Journal of Heart Failure 1, 5
The combination provides additive blood pressure reduction without redundancy—chlorthalidone addresses volume and blood pressure control while spironolactone provides disease-modifying effects on cardiac remodeling, according to the European Heart Journal 1, 5

Before continuing spironolactone with chlorthalidone, verify serum potassium <5.0 mmol/L, serum creatinine <220 μmol/L, and eGFR >30 mL/min/1.73m², as recommended by Praxis Medical Insights 6, 7
Check potassium and creatinine at 1 week and 4 weeks after adding chlorthalidone, then at 1, 2, 3, and 6 months, and subsequently every 6 months during stable therapy, according to Praxis Medical Insights 6

Maintain spironolactone at 25 mg once daily when combined with losartan and chlorthalidone, as this is the target dose for most HFpEF patients and provides optimal benefit-to-risk ratio, as recommended by Praxis Medical Insights 6, 4
Start chlorthalidone at 12.5-25 mg once daily, as this provides effective blood pressure reduction while minimizing electrolyte disturbances, according to the European Journal of Heart Failure 5

Never combine spironolactone with both an ACE inhibitor and an ARB simultaneously, as this dramatically increases hyperkalemia risk without additional benefit, as warned by Praxis Medical Insights 6
Do not discontinue spironolactone preemptively due to fear of hyperkalemia—the mortality and morbidity benefits in HFpEF justify continuation with appropriate monitoring, according to the European Heart Journal and Circulation 1, 3

The combination of losartan and spironolactone provides complementary renal protection in diabetic nephropathy through different mechanisms of reducing proteinuria and slowing GFR decline, as reported in Kidney International 8
Patients with diabetic nephropathy require more frequent monitoring than standard protocols, particularly during the first 3 months after adding chlorthalidone, and consider checking potassium and creatinine at 3-5 days after initiating chlorthalidone, as recommended by Praxis Medical Insights 6